Becton Dickinson (BD) has received a CE mark for its expanded BD COR system, which now includes MX, a new instrument for high-throughput molecular testing for infectious diseases.

The new instrument is based on the company’s BD MAX polymerase chain-reaction platform, a medium-throughput system intended for settings like hospital labs. BD plans to use the BD MAX menu of infectious disease tests to create assays that can be performed in high-throughput central reference labs.

The first test available on the MX instrument is the BD CTGCTV2, which detects the three most prevalent nonviral sexually transmitted infections — Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis.